682 related articles for article (PubMed ID: 23199963)
1. Implementation of human papillomavirus immunization in the developing world.
Kane MA; Serrano B; de Sanjosé S; Wittet S
Vaccine; 2012 Nov; 30 Suppl 5():F192-200. PubMed ID: 23199963
[TBL] [Abstract][Full Text] [Related]
2. Reframing cervical cancer prevention. Expanding the field towards prevention of human papillomavirus infections and related diseases.
Bosch FX; Tsu V; Vorsters A; Van Damme P; Kane MA
Vaccine; 2012 Nov; 30 Suppl 5():F1-11. PubMed ID: 23199951
[TBL] [Abstract][Full Text] [Related]
3. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
4. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus vaccine introduction--the first five years.
Markowitz LE; Tsu V; Deeks SL; Cubie H; Wang SA; Vicari AS; Brotherton JM
Vaccine; 2012 Nov; 30 Suppl 5():F139-48. PubMed ID: 23199957
[TBL] [Abstract][Full Text] [Related]
7. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.
Sankaranarayanan R; Anorlu R; Sangwa-Lugoma G; Denny LA
Vaccine; 2013 Dec; 31 Suppl 5():F47-52. PubMed ID: 24331747
[TBL] [Abstract][Full Text] [Related]
8. Global implementation of human papillomavirus (HPV) vaccine: lessons from hepatitis B vaccine.
Kane MA
Gynecol Oncol; 2010 May; 117(2 Suppl):S32-5. PubMed ID: 20129654
[TBL] [Abstract][Full Text] [Related]
9. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
Poljak M
Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
[TBL] [Abstract][Full Text] [Related]
11. Upgrading public health programs for human papillomavirus prevention and control is possible in low- and middle-income countries.
Steben M; Jeronimo J; Wittet S; Lamontagne DS; Ogilvie G; Jensen C; Smith J; Franceschi S
Vaccine; 2012 Nov; 30 Suppl 5():F183-91. PubMed ID: 23199962
[TBL] [Abstract][Full Text] [Related]
12. [Introduction of vaccination against human papillomavirus in developing countries: update and perspectives].
Hessel L
Med Trop (Mars); 2009 Aug; 69(4):323-6. PubMed ID: 19725378
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
[TBL] [Abstract][Full Text] [Related]
14. Progress toward implementation of human papillomavirus vaccination--the Americas, 2006-2010.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Oct; 60(40):1382-4. PubMed ID: 21993342
[TBL] [Abstract][Full Text] [Related]
15. Recommendations for cervical cancer prevention in Asia Pacific.
Garland SM; Cuzick J; Domingo EJ; Goldie SJ; Kim YT; Konno R; Parkin DM; Qiao YL; Sankaranarayanan R; Stern PL; Tay SK; Bosch FX
Vaccine; 2008 Aug; 26 Suppl 12():M89-98. PubMed ID: 18945418
[TBL] [Abstract][Full Text] [Related]
16. Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine.
Monsonego J; Cortes J; Greppe C; Hampl M; Joura E; Singer A
Vaccine; 2010 Nov; 28(51):8065-72. PubMed ID: 20971114
[TBL] [Abstract][Full Text] [Related]
17. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
Adams M; Jasani B; Fiander A
Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
[TBL] [Abstract][Full Text] [Related]
18. Mathematical models of cervical cancer prevention in the Asia Pacific region.
Goldie SJ; Diaz M; Kim SY; Levin CE; Van Minh H; Kim JJ
Vaccine; 2008 Aug; 26 Suppl 12():M17-29. PubMed ID: 18945411
[TBL] [Abstract][Full Text] [Related]
19. A qualitative analysis of South African women's knowledge, attitudes, and beliefs about HPV and cervical cancer prevention, vaccine awareness and acceptance, and maternal-child communication about sexual health.
Francis SA; Battle-Fisher M; Liverpool J; Hipple L; Mosavel M; Soogun S; Mofammere N
Vaccine; 2011 Nov; 29(47):8760-5. PubMed ID: 21855591
[TBL] [Abstract][Full Text] [Related]
20. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.
Goldie SJ; O'Shea M; Diaz M; Kim SY
Reprod Health Matters; 2008 Nov; 16(32):86-96. PubMed ID: 19027626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
